Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
06 08 2019
Historique:
entrez: 1 8 2019
pubmed: 1 8 2019
medline: 5 1 2021
Statut: ppublish

Résumé

Background We aimed to assess the prevalence and degree of overlap of potential embolic sources (PES) in patients with embolic stroke of undetermined source (ESUS). Methods and Results In a pooled data set derived from 3 prospective stroke registries, patients were categorized in ≥1 groups according to the PES that was/were identified. We categorized PES as follows: atrial cardiopathy, atrial fibrillation diagnosed during follow-up, arterial disease, left ventricular disease, cardiac valvular disease, patent foramen ovale, and cancer. In 800 patients with ESUS (43.1% women; median age, 67.0 years), 3 most prevalent PES were left ventricular disease, arterial disease, and atrial cardiopathy, which were present in 54.4%, 48.5%, and 45.0% of patients, respectively. Most patients (65.5%) had >1 PES, whereas only 29.7% and 4.8% of patients had a single or no PES, respectively. In 31.1% of patients, there were ≥3 PES present. On average, each patient had 2 PES (median, 2). During a median follow-up of 3.7 years, stroke recurrence occurred in 101 (12.6%) of patients (23.3 recurrences per 100 patient-years). In multivariate analysis, the risk of stroke recurrence was higher in the atrial fibrillation group compared with other PES, but not statistically different between patients with 0 to 1, 2, or ≥3 PES. Conclusions There is major overlap of PES in patients with ESUS. This may possibly explain the negative results of the recent large randomized controlled trials of secondary prevention in patients with ESUS and offer a rationale for a randomized controlled trial of combination of anticoagulation and aspirin for the prevention of stroke recurrence in patients with ESUS. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02766205.

Identifiants

pubmed: 31364451
doi: 10.1161/JAHA.119.012858
pmc: PMC6761628
doi:

Banques de données

ClinicalTrials.gov
['NCT02766205']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012858

Références

J Stroke Cerebrovasc Dis. 2016 Dec;25(12):2975-2980
pubmed: 27612625
Int J Stroke. 2019 Feb;14(2):207-214
pubmed: 30196789
Circ Heart Fail. 2017 May;10(5):
pubmed: 28500254
N Engl J Med. 1992 Jan 23;326(4):221-5
pubmed: 1727976
Cochrane Database Syst Rev. 2017 Dec 15;12:CD011088
pubmed: 29244199
Am Heart J. 2018 Mar;197:124-132
pubmed: 29447772
Can J Cardiol. 2017 Aug;33(8):1027-1035
pubmed: 28754388
Stroke. 2015 Aug;46(8):2087-93
pubmed: 26159795
Stroke. 2011 Jan;42(1):30-6
pubmed: 21127299
Stroke. 2017 Apr;48(4):867-872
pubmed: 28265016
N Engl J Med. 2018 Feb 22;378(8):699-707
pubmed: 29466159
Stroke. 2010 Nov;41(11):2491-8
pubmed: 20930152
Cardiovasc Drugs Ther. 2017 Jun;31(3):319-324
pubmed: 28643219
Am Heart J. 2018 Jun;200:17-23
pubmed: 29898844
J Neurol Sci. 2017 Nov 15;382:49-52
pubmed: 29111018
Circulation. 2017 Dec 19;136(25):2403-2405
pubmed: 29255121
Turk Kardiyol Dern Ars. 2017 Sep;45(Suppl 4):1-7
pubmed: 28947723
Stroke. 2015 Jun;46(6):1488-93
pubmed: 25908460
Stroke. 2015 Jan;46(1):176-81
pubmed: 25378429
Stroke. 2016 Sep;47(9):2278-85
pubmed: 27507859
Eur Stroke J. 2016 Sep;1(3):146-154
pubmed: 31008276
Lancet Neurol. 2014 Apr;13(4):429-38
pubmed: 24646875
Neurology. 2019 Jun 4;92(23):e2644-e2652
pubmed: 31068479
J Zhejiang Univ Sci B. 2017 Jul;18(7):567-576
pubmed: 28681581
N Engl J Med. 1994 Dec 1;331(22):1474-9
pubmed: 7969297
Neuroepidemiology. 2016;47(1):53-8
pubmed: 27529786
J Arthroplasty. 2017 Sep;32(9):2911-2919.e6
pubmed: 28522244
J Am Heart Assoc. 2019 Aug 6;8(15):e012858
pubmed: 31364451
Int J Stroke. 2017 Oct;12(8):910-914
pubmed: 28585903
Clin Ther. 2017 Jul;39(7):1291-1312.e8
pubmed: 28606562

Auteurs

George Ntaios (G)

Department of Internal Medicine School of Medicine Larissa University Hospital University of Thessaly Larissa Greece.

Kalliopi Perlepe (K)

Department of Internal Medicine School of Medicine Larissa University Hospital University of Thessaly Larissa Greece.

Dimitrios Lambrou (D)

Department of Internal Medicine School of Medicine Larissa University Hospital University of Thessaly Larissa Greece.

Gaia Sirimarco (G)

Stroke Center and Neurology Service Department of Clinical Neurosciences Centre Hospitalier Universitaire Vaudois and University of Lausanne Switzerland.

Davide Strambo (D)

Stroke Center and Neurology Service Department of Clinical Neurosciences Centre Hospitalier Universitaire Vaudois and University of Lausanne Switzerland.

Ashraf Eskandari (A)

Stroke Center and Neurology Service Department of Clinical Neurosciences Centre Hospitalier Universitaire Vaudois and University of Lausanne Switzerland.

Efstathia Karagkiozi (E)

Department of Internal Medicine School of Medicine Larissa University Hospital University of Thessaly Larissa Greece.

Anastasia Vemmou (A)

Department of Clinical Therapeutics Medical School of Athens Alexandra Hospital Athens Greece.

Eleni Koroboki (E)

Department of Clinical Therapeutics Medical School of Athens Alexandra Hospital Athens Greece.

Efstathios Manios (E)

Department of Clinical Therapeutics Medical School of Athens Alexandra Hospital Athens Greece.

Konstantinos Makaritsis (K)

Department of Internal Medicine School of Medicine Larissa University Hospital University of Thessaly Larissa Greece.

Konstantinos Vemmos (K)

Department of Clinical Therapeutics Medical School of Athens Alexandra Hospital Athens Greece.

Patrik Michel (P)

Stroke Center and Neurology Service Department of Clinical Neurosciences Centre Hospitalier Universitaire Vaudois and University of Lausanne Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH